Table 3.

Diagnostic performance indices and 95% confidence intervals

Variable	All patients	Premenopausal	Postmenopausal
ADNEX
Sensitivity	62.5 (40.6-81.2)	59.1 (36.4-79.3)	50.0 (1.3-98.7)
Specificity	79.6 (74.2-84.3)	85.3 (80.1-89.5)	100 (84.6-100)
PPV	22.0 (12.9-33.7)	27.1 (15.3-41.9)	100 (2.5-100)
NPV	95.8 (92.2-98.1)	95.8 (92.1-98.0)	95.7 (78.1-99.9)
LR+	3.07	4.02	NA
LR−	0.47	0.48	0.50
AUC	74.6 (69.1-79.6)	76.6 (71.0-81.6)	61.4 (39.5-80.3)
P	<0.001	<0.001	0.602
RMI
Sensitivity	83.3 (62.6-95.3)	86.4 (65.1-97.1)	50.0 (1.3-98.7)
Specificity	29.6 (24.1-35.6)	27.3 (21.8-33.4)	90.9 (70.8-98.9)
PPV	9.8 (6.1-14.8)	9.9 (6.1-15.0)	33.3 (14.0-90.5)
NPV	95.1 (87.8-98.6)	95.6 (87.7-99.1)	95.2 (76.2-99.9)
LR+	1.18	1.19	5.50
LR−	0.56	0.50	0.55
AUC	51.7 (45.7-57.6)	51.4 (45.1-57.6)	56.8 (35.2-76.7)
P	0.785	0.831	0.754
Maximal diameter of lesion
Sensitivity	66.7 (44.7-84.4)	86.4 (65.1-97.1)	100 (15.8-100)
Specificity	61.1 (54.9-67.1)	45.0 (38.5-51.5)	40.9 (20.7-63.6)
PPV	13.7 (8.0-21.2)	12.7 (7.8-19.1)	13.3 (1.7-40.4)
NPV	95.2 (90.8-97.9)	97.3 (92.3-99.4)	100 (66.4-100)
LR+	1.72	1.57	1.69
LR−	0.55	0.30	0.00
AUC	67.4 (61.7-72.9)	69.5 (63.5-75.0)	60.2 (38.4-79.4)
P	0.005	0.003	0.638
CA-125
Sensitivity	41.7 (22.1-63.4)	40.9 (20.7-63.6)	50.0 (1.3-98.7)
Specificity	80.8 (75.4-85.4)	81.1 (75.5-85.9)	95.5 (77.2-99.9)
PPV	16.7 (8.3-28.6)	16.7 (7.9-29.3)	50.3 (1.3-98.7)
NPV	93.8 (89.7-96.5)	93.7 (89.4-96.6)	95.4 (77.2-99.9)
LR+	2.17	16.7 (7.9-29.3)	11.00
LR−	0.72	93.7 (89.4-96.6)	0.52
AUC	59.8 (53.9-65.6)	60.4 (54.1-66.4)	52.3 (31.1-72.8)
P	0.111	0.108	0.917

PPV: Positive predictive value, NPV: Negative predictive value, RMI: Risk of malignancy index, AUC: Area under the curve, LR+: Positive likelihood, LR−: Negative likelihood